Page 34 - 2021 Spring CMTA Report - Special Research Edition

ACCELERATING

RESEARCH

EMPOWERING

PATIENTS

What Progress Have We Made?

The CMTA has invested over $17M in recent years and our
strategy outlines investments of another $10M in the next few
years to help bring CMT drugs to market.
• We currently have over 50 active research projects
with the top labs around the world, all vetted through our
advisory board, comprised of 30 of the top CMT scientists
from across the globe.
• The CMTA now has partnership agreements with more than
30 academic, pharmaceutical, biotech and service companies
across three continents. They are leaders in the latest genetic
and neurological technologies (such as CRISPR, gene therapy,
gene silencing, and axon and muscle regeneration).
These partners are actively working with the CMTA to develop
treatments for the 3 million patients living with CMT.
• The CMTA has a network of more than 40 CMT Centers of
Excellence, 70 branches, and a partnership with the Inherited
Neuropathy Consortium (INC). Through this network we are
building patient registries and outcome measures for our
pharmaceutical and biotech partners to aid in fast and
effective clinical trials.
The CMTA was founded by a patient, and to this day is powered
by a community of patients who are all rallying behind our mission.
With the largest constituency of CMT families around the world,
the CMTA actively works with the patient community in the drug
development process to ensure patients are our partners every
step of the way.

STAR IS THE BRIGHTEST BEACON OF HOPE IN

ACHIEVING OUR VISION OF A WORLD WITHOUT CMT.

34